Original article| Volume 207, ISSUE 4, P160-163, April 2014

Genetic anticipation of familial breast cancer with or without BRCA mutation in the Korean population

      We investigated genetic anticipation of breast or ovarian cancer in patients with familial breast cancer. Among 201 patients with breast cancer who had a family history of breast or ovarian cancer, 95 families had affected familial members in the previous generation. Of these families, 2 were excluded because of insufficient data. From the 93 eligible families, 112 and 111 members were identified in the previous and proband generations, respectively. BRCA mutations were detected in 26 (28.0%) of the 93 probands. The median age at diagnosis of the first generation was 57 years and of the second generation was 40 years, which was a significant difference. The result from the mixed-effects model also demonstrated significant genetic anticipation (P < 0.0001). The expected age difference at onset of breast or ovarian cancer between the two generations was 17.06 years. BRCA mutation status did not influence the generational difference in age at diagnosis (17.99 vs. 16.62 y, P = 0.3973). Genetic counseling and early screening should be provided to women whose parent had a breast or ovarian cancer diagnosis.


      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'


      Subscribe to Cancer Genetics
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect


        • Timshel S.
        • Therkildsen C.
        • Bendahl P.O.
        • et al.
        An effect from anticipation also in hereditary nonpolyposis colorectal cancer families without identified mutations.
        Cancer Epidemiol. 2009; 33: 231-234
        • Nilbert M.
        • Timshel S.
        • Bernstein I.
        • et al.
        Role for genetic anticipation in Lynch syndrome.
        J Clin Oncol. 2009; 27: 360-364
        • Alexandrescu D.T.
        • Garino A.
        • Brown-Balem K.A.
        • et al.
        Anticipation in families with Hodgkin's and non-Hodgkin's lymphoma in their pedigree.
        Leuk Lymphoma. 2006; 47: 2115-2127
        • Horwitz M.
        • Goode E.L.
        • Jarvik G.P.
        Anticipation in familial leukemia.
        Am J Hum Genet. 1996; 59: 990-998
        • McFaul C.D.
        • Greenhalf W.
        • Earl J.
        • et al.
        Anticipation in familial pancreatic cancer.
        Gut. 2006; 55: 252-258
        • Goldberg J.M.
        • Piver M.S.
        • Jishi M.F.
        • et al.
        Age at onset of ovarian cancer in women with a strong family history of ovarian cancer.
        Gynecol Oncol. 1997; 66: 3-9
        • Hsu L.
        • Zhao L.P.
        • Malone K.E.
        • et al.
        Assessing changes in ages at onset over successive generation: an application to breast cancer.
        Genet Epidemiol. 2000; 18: 17-32
        • Peixoto A.
        • Salgueiro N.
        • Santos C.
        • et al.
        BRCA1 and BRCA2 germline mutational spectrum and evidence for genetic anticipation in Portuguese breast/ovarian cancer families.
        Fam Cancer. 2006; 5: 379-387
        • Dagan E.
        • Gershoni-Baruch R.
        Anticipation in hereditary breast cancer.
        Clin Genet. 2002; 62: 147-150
        • Martinez-Delgado B.
        • Yanowsky K.
        • Inglada-Perez L.
        • et al.
        Genetic anticipation is associated with telomere shortening in hereditary breast cancer.
        PLoS Genet. 2011; 7: e1002182
        • Litton J.K.
        • Ready K.
        • Chen H.
        • et al.
        Earlier age of onset of BRCA mutation-related cancers in subsequent generations.
        Cancer. 2012; 118: 321-325
        • Miki Y.
        • Swensen J.
        • Shattuck-Eidens D.
        • et al.
        A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1.
        Science. 1994; 266: 66-71
        • Wooster R.
        • Bignell G.
        • Lancaster J.
        • et al.
        Identification of the breast cancer susceptibility gene BRCA2.
        Nature. 1995; 378: 789-792
        • Chen S.
        • Parmigiani G.
        Meta-analysis of BRCA1 and BRCA2 penetrance.
        J Clin Oncol. 2007; 25: 1329-1333
        • Ahn S.H.
        • Yoo K.Y.
        Chronological changes of clinical characteristics in 31,115 new breast cancer patients among Koreans during 1996-2004.
        Breast Cancer Res Treat. 2006; 99: 209-214
        • Son B.H.
        • Kwak B.S.
        • Kim J.K.
        • et al.
        Changing patterns in the clinical characteristics of Korean patients with breast cancer during the last 15 years.
        Arch Surg. 2006; 141: 155-160
        • Han S.A.
        • Kim S.W.
        • Kang E.
        • et al.
        The prevalence of BRCA mutations among familial breast cancer patients in Korea: results of the Korean Hereditary Breast Cancer study.
        Fam Cancer. 2013; 12: 75-81
        • Son B.H.
        • Ahn S.H.
        • Kim S.W.
        • et al.
        Prevalence of BRCA1 and BRCA2 mutations in non-familial breast cancer patients with high risks in Korea: the Korean Hereditary Breast Cancer (KOHBRA) Study.
        Breast Cancer Res Treat. 2012; 133: 1143-1152
        • Noh J.M.
        • Choi D.H.
        • Baek H.
        • et al.
        Associations between BRCA mutations in high-risk breast cancer patients and familial cancers other than breast or ovary.
        J Breast Cancer. 2012; 15: 283-287
        • Jang J.H.
        • Lee J.E.
        • Kwon M.J.
        • et al.
        Spectra of BRCA1 and BRCA2 mutations in Korean patients with breast cancer: the importance of whole-gene sequencing.
        J Hum Genet. 2012; 57: 212-215
        • Larsen K.
        • Petersen J.
        • Bernstein I.
        • et al.
        A parametric model for analyzing anticipation in genetically predisposed families.
        Stat Appl Genet Mol Biol. 2009; 8 (Article26)
        • King M.C.
        • Marks J.H.
        • Mandell J.B.
        Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2.
        Science. 2003; 302: 643-646
        • Turnbull C.
        • Rahman N.
        Genetic predisposition to breast cancer: past, present, and future.
        Annu Rev Genomics Hum Genet. 2008; 9: 321-345
        • Snape K.
        • Ruark E.
        • Tarpey P.
        • et al.
        Predisposition gene identification in common cancers by exome sequencing: insights from familial breast cancer.
        Breast Cancer Res Treat. 2012; 134: 429-433
        • Hindorff L.A.
        • Sethupathy P.
        • Junkins H.A.
        • et al.
        Potential etiologic and functional implications of genome-wide association loci for human diseases and traits.
        Proc Natl Acad Sci USA. 2009; 106: 9362-9367
        • Narod S.A.
        Earlier age of onset in BRCA carriers-anticipation or cohort effect?: a countercurrents series.
        Curr Oncol. 2011; 18: 257-258
        • Boonstra P.S.
        • Gruber S.B.
        • Raymond V.M.
        • et al.
        A review of statistical methods for testing genetic anticipation: looking for an answer in Lynch syndrome.
        Genet Epidemiol. 2010; 34: 756-768
        • Yoo K.Y.
        Cancer control activities in the Republic of Korea.
        Jpn J Clin Oncol. 2008; 38: 327-333
      1. National Comprehensive Cancer Network NCCN Clinical Practice Guidelines in Oncology; Genetic/Familial High-Risk Assessment: Breast and Ovarian v.4.2013. Available at: Accessed on December 23, 2013.

        • Lee C.H.
        • Dershaw D.D.
        • Kopans D.
        • et al.
        Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer.
        J Am Coll Radiol. 2010; 7: 18-27
        • Tilanus-Linthorst M.M.
        • Lingsma H.F.
        • Evans D.G.
        • et al.
        Optimal age to start preventive measures in women with BRCA1/2 mutations or high familial breast cancer risk.
        Int J Cancer. 2013; 133: 156-163